Albutrepenonacog Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Albutrepenonacog alfa: From Hemophilia to Pseudo-von Willebrand Disease
One-Sentence Summary
Albutrepenonacog alfa is a long-acting recombinant factor IX albumin fusion protein, originally used to treat hemophilia (factor IX deficiency). The TxGNN model predicts it may be effective for pseudo-von Willebrand disease, but no clinical trials and no publications currently support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia; symptomatic form of hemophilia in female carriers |
| Predicted New Indication | Pseudo-von Willebrand disease |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, albutrepenonacog alfa is a recombinant factor IX fused to albumin (rIX-FP). It replaces missing factor IX in the intrinsic coagulation pathway, and its efficacy in hemophilia is established.
Pseudo-von Willebrand disease is a different kind of problem. It is a platelet-type disorder caused by a gain-of-function change in platelet GPIbα, which increases binding to von Willebrand factor (VWF). The defect lies in the platelet–VWF interaction, not in factor IX deficiency. There is therefore no clear mechanistic reason for factor IX replacement to help.
The high TxGNN score most likely reflects a network-level association with bleeding disorders rather than a true mechanistic link. The other top predictions (rank 2 to 10) are mostly platelet function disorders or thrombotic/hypercoagulable conditions. They share the same weakness. Several raise a safety concern, such as thrombotic thrombocytopenic purpura and inherited thrombophilia, where adding a procoagulant factor could be harmful.
The most biologically plausible prediction on the list is acquired coagulation factor deficiency (score 98.58%). Even so, such deficiencies usually involve several factors and are typically managed with plasma, prothrombin complex concentrate or vitamin K. Single-factor replacement also carries a thrombotic risk in this setting. This remains a research question, not a supported indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15811P | IDELVION Powder and Solvent for Solution for Injection 250IU/vial | Lyophilised powder for injection | Not specified in the data compiled for this report |
| SIN15812P | IDELVION Powder and Solvent for Solution for Injection 500IU/vial | Lyophilised powder for injection | Not specified in the data compiled for this report |
| SIN15813P | IDELVION Powder and Solvent for Solution for Injection 1000IU/vial | Lyophilised powder for injection | Not specified in the data compiled for this report |
| SIN15814P | IDELVION Powder and Solvent for Solution for Injection 2000IU/vial | Lyophilised powder for injection | Not specified in the data compiled for this report |
All four registrations are valid single-ingredient products from CSL Behring GmbH.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (evidence level L5). There are no clinical trials or publications. The biology does not support factor IX replacement in a platelet-VWF disorder. The data compiled for this report also lacks mechanism and safety information, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Mechanism of action data for the drug (for example from DrugBank)
- A literature and trial search to test whether any real-world evidence exists for pseudo-von Willebrand disease
- Consideration of re-prioritising acquired coagulation factor deficiency, the most plausible predicted indication, as a research question, with a specific assessment of thrombotic risk
- Confirmation of the approved indication text for the four Singapore registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.